FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, today announced […]
Newly Issued Claims Extend Patent Protection to Year 2039 for Nyxol®Combination Therapy for Presbyopia […]
Launch of Psychedelics DNA Test Kit,
Phase 1 clinical trial for DMT progressing as planned,
Pre-clinical In Vivo work scheduled to start at Israeli CRO […]
Reported Positive Data in First Pivotal Phase 3 Trial for Nyxol Eye Drops with Plans to Advance Towards NDA Submission and Commercialization in Reversal of Mydriasis Indication […]
● Compositions and Methods for Enhancing Anti-viral Therapies ●
[…]
Interview with Timothy Ko, CEO […]
Following the Meeting, Mr. Adrian Smith, Mr. Collin Kim, Mr. Ken Chung, Mr. Kosta Tsoutsis and Mr. Mike Collins will serve on the board of directors. […]
PurCann, a subsidiary of SiliCycle, is recognized for its unique expertise in the Extraction-Purification and commercialization of cannabinoids. […]
During the interview, Mr. Joyce discusses recent data-driven milestones that reinforce the potential for Sigyn Therapy™ to overcome the limitations of previous strategies to treat sepsis and other life-threatening inflammatory conditions. […]
Copyright © 2019 The Wall Street Analyst, LLC. All rights reserved. Website by MyWebsiteSpot.com
